A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

M. W. Kline; C. V. Fletcher; A. T. Harris; K. D. Evans; R. C. Brundage; R. P. Remmel; N. R. Calles; S. B. Kirkpatrick; C. Simon

doi:10.1016/S0022-3476(98)70039-3

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

M. W. Kline, C. V. Fletcher, A. T. Harris, K. D. Evans, R. C. Brundage, R. P. Remmel, N. R. Calles, S. B. Kirkpatrick, C. Simon

Research output: Contribution to journal › Article › peer-review

51 Scopus citations

Abstract

Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

Original language	English (US)
Pages (from-to)	543-546
Number of pages	4
Journal	Journal of Pediatrics
Volume	132
Issue number	3 I
DOIs	https://doi.org/10.1016/S0022-3476(98)70039-3
State	Published - 1998
Externally published	Yes

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health

Access to Document

10.1016/S0022-3476(98)70039-3

Cite this

Kline, M. W., Fletcher, C. V., Harris, A. T., Evans, K. D., Brundage, R. C., Remmel, R. P., Calles, N. R., Kirkpatrick, S. B., & Simon, C. (1998). A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus. Journal of Pediatrics, 132(3 I), 543-546. https://doi.org/10.1016/S0022-3476(98)70039-3

Kline, MW, Fletcher, CV, Harris, AT, Evans, KD, Brundage, RC, Remmel, RP, Calles, NR, Kirkpatrick, SB & Simon, C 1998, 'A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus', Journal of Pediatrics, vol. 132, no. 3 I, pp. 543-546. https://doi.org/10.1016/S0022-3476(98)70039-3

@article{602e2cd51b6a432d8f6a2c5049dd9b79,

title = "A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus",

abstract = "Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.",

author = "Kline, {M. W.} and Fletcher, {C. V.} and Harris, {A. T.} and Evans, {K. D.} and Brundage, {R. C.} and Remmel, {R. P.} and Calles, {N. R.} and Kirkpatrick, {S. B.} and C. Simon",

year = "1998",

doi = "10.1016/S0022-3476(98)70039-3",

language = "English (US)",

volume = "132",

pages = "543--546",

journal = "Journal of Pediatrics",

issn = "0022-3476",

publisher = "Elsevier Inc.",

number = "3 I",

}

TY - JOUR

T1 - A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

AU - Kline, M. W.

AU - Fletcher, C. V.

AU - Harris, A. T.

AU - Evans, K. D.

AU - Brundage, R. C.

AU - Remmel, R. P.

AU - Calles, N. R.

AU - Kirkpatrick, S. B.

AU - Simon, C.

PY - 1998

Y1 - 1998

N2 - Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

AB - Twelve children infected with the human immunodeficiency virus were treated orally with indinavir, stavudine, plus didanosine for 12 to 48 weeks. Therapy was limited in some cases by nonadherence, intolerance, toxicity, and virologic failure. Marked increases in CD4+ lymphocyte counts and decreases in plasma human immunodeficiency virus RNA concentrations suggest that the regimen has potent antiviral activity.

UR - http://www.scopus.com/inward/record.url?scp=0031894889&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031894889&partnerID=8YFLogxK

U2 - 10.1016/S0022-3476(98)70039-3

DO - 10.1016/S0022-3476(98)70039-3

M3 - Article

C2 - 9544920

AN - SCOPUS:0031894889

SN - 0022-3476

VL - 132

SP - 543

EP - 546

JO - Journal of Pediatrics

JF - Journal of Pediatrics

IS - 3 I

ER -

A pilot study of combination therapy with indinavir, stavudine (d4T), and didanosine (ddI) in children infected with the human immunodeficiency virus

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this